• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Semler Scientific Inc. (Amendment)

    9/14/23 5:15:18 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SMLR alert in real time by email
    SC 13D/A 1 sc13da210608006_09142023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    Semler Scientific, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    81684M104

    (CUSIP Number)

    ERIC SEMLER

    c/o TCS CAPITAL MANAGEMENT, LLC

    142 West 57th Street, 11th Floor

    New York, New York 10019

     

    ANDREW M. FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    September 11, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 81684M104

      1   NAME OF REPORTING PERSON  
             
            Eric Semler  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF, AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         568,221  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         77,771  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              568,221  
        10   SHARED DISPOSITIVE POWER  
               
              77,771  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            645,992  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            9.4%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

    * Based upon an aggregate of 6,873,196 shares of the Issuer’s common stock outstanding as of September 1, 2023, as reported in the Issuer’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 8, 2023.

      

    2

    CUSIP No. 81684M104

      1   NAME OF REPORTING PERSON  
             
            TCS Capital Advisors, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            New York  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         77,771  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              77,771  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            77,771  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

    * Based upon an aggregate of 6,873,196 shares of the Issuer’s common stock outstanding as of September 1, 2023, as reported in the Issuer’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 8, 2023.

      

    3

    CUSIP No. 81684M104

     

      1   NAME OF REPORTING PERSON  
             
            TCS Capital Management, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         77,771  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              77,771  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            77,771  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

    * Based upon an aggregate of 6,873,196 shares of the Issuer’s common stock outstanding as of September 1, 2023, as reported in the Issuer’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 8, 2023.

      

    4

    CUSIP No. 81684M104

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 2.Identity and Background.

    Item 2 is hereby amended and restated to read as follows:

    (a)       This statement is filed by:

    (i)TCS Capital Advisors, LLC, a New York limited liability company (“TCS Advisors”);
    (ii)TCS Capital Management, LLC, a Delaware limited liability company (“TCS Management”); and
    (iii)Eric Semler.

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

    (b)       The address of the principal office of each of TCS Advisors, TCS Management and Mr. Semler is 142 West 57th Street, 11th Floor, New York, NY 10019.

    (c)       The principal business of TCS Advisors is investing in securities. The principal business of TCS Management is serving as the investment manager of TCS Advisors. Mr. Semler serves as the managing member of TCS Management.

    (d)       No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e)       No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f)       TCS Advisors is organized under the laws of the State of New York. TCS Management is organized under the laws of the State of Delaware. Mr. Semler is a citizen of the United States of America.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended to add the following:

    The shares of Common Stock purchased by TCS Advisors were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 77,771 shares directly beneficially owned by TCS Advisors is approximately $2,147,273, excluding brokerage commissions.

    5

    CUSIP No. 81684M104

    Item 5.Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated to read as follows:

    The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 6,873,196 shares of Common Stock outstanding as of September 1, 2023, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 8, 2023.

    A.TCS Advisors
    (a)As of the close of business on September 14, 2023, TCS Advisors directly owned 77,771 shares of Common Stock.

    Percentage: Less than 1%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 77,771
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 77,771
    (c)The transactions in the shares of Common Stock by TCS Advisors during the past 60 days are set forth in Schedule A and are incorporated herein by reference.
    B.TCS Management
    (a)TCS Management, as the investment manager of TCS Advisors, may be deemed the beneficial owner of the 77,771 shares of Common Stock owned by TCS Advisors.

    Percentage: Less than 1%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 77,771
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 77,771
    (c)TCS Management has not entered into any transactions in the shares of Common Stock during the past 60 days. The transactions in the shares of Common Stock on behalf of TCS Advisors during the past 60 days are set forth in Schedule A and are incorporated herein by reference.
    C.Mr. Semler
    (a)As of the close of business on September 14, 2023, Mr. Semler directly owned 568,221 shares of Common Stock. As the managing member of TCS Management, Mr. Semler may be deemed the beneficial owner of the 77,771 shares of Common Stock owned by TCS Advisors.

    Percentage: Approximately 9.4%

    6

    CUSIP No. 81684M104

    (b)1. Sole power to vote or direct vote: 568,221
    2. Shared power to vote or direct vote: 77,771
    3. Sole power to dispose or direct the disposition: 568,221
    4. Shared power to dispose or direct the disposition: 77,771
    (c)Mr. Semler has not entered into any transactions in the shares of Common Stock during the past 60 days. The transactions in the shares of Common Stock on behalf of TCS Advisors during the past 60 days are set forth in Schedule A and are incorporated herein by reference.

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any shares of Common Stock he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the shares of Common Stock reported herein that he or it does not directly own.

    (d)No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Issuer’s Common Stock.
    (e)Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    On September 14, 2023, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following:

    99.1Joint Filing Agreement by and among TCS Capital Advisors, LLC, TCS Capital Management, LLC and Eric Semler, dated September 14, 2023.

     

    7

    CUSIP No. 81684M104

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: September 14, 2023

      TCS CAPITAL ADVISORS, LLC
       
      By: TCS CAPITAL MANAGEMENT, LLC
    its investment manager
       
      By:

    /s/ Eric Semler

        Name: Eric Semler
        Title: Managing Member

     

     

      TCS CAPITAL MANAGEMENT, LLC
       
      By:

    /s/ Eric Semler

        Name: Eric Semler
        Title: Managing Member

     

     

     

    /s/ Eric Semler

      ERIC SEMLER

     

    8

    CUSIP No. 81684M104

    SCHEDULE A

    Transactions in Securities of the Issuer During the Past 60 Days

    Nature of the Transaction

    Securities

    Purchased/(Sold)

    Price Per

    Security($)

    Date of

    Purchase/Sale

     

    TCS CAPITAL ADVISORS, LLC

    Purchase of Common Stock 25,000 26.98 09/11/2023
    Purchase of Common Stock 25,903 27.70 09/12/2023
    Purchase of Common Stock 26,868 28.11 09/13/2023

     

    Get the next $SMLR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMLR

    DatePrice TargetRatingAnalyst
    7/28/2025Overweight
    Cantor Fitzgerald
    7/8/2025$101.00Buy
    The Benchmark Company
    11/2/2022$60.00 → $45.00Buy → Neutral
    B. Riley Securities
    3/7/2022$145.00 → $70.00Buy
    B. Riley Securities
    11/2/2021$175.00 → $145.00Buy
    B. Riley Securities
    10/26/2021$151.00 → $175.00Buy
    B. Riley Securities
    More analyst ratings

    $SMLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Murphy-Chutorian Douglas exercised 60,000 shares at a strike of $2.56, sold $873,566 worth of shares (28,604 units at $30.54), gifted 31,396 shares and received a gift of 31,396 shares (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    8/26/25 4:05:20 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Brunell Natalie

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    6/26/25 4:15:11 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Semler Eric exercised 6,750 shares at a strike of $23.32, increasing direct ownership by 1% to 636,346 units (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    6/12/25 6:01:48 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Semler Scientific

    Cantor Fitzgerald initiated coverage of Semler Scientific with a rating of Overweight

    7/28/25 9:00:02 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    The Benchmark Company initiated coverage on Semler Scientific with a new price target

    The Benchmark Company initiated coverage of Semler Scientific with a rating of Buy and set a new price target of $101.00

    7/8/25 8:33:26 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Semler Scientific from Buy to Neutral and set a new price target of $45.00 from $60.00 previously

    11/2/22 6:23:13 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semler Eric was granted 1,318 shares and bought $1,896,500 worth of shares (50,000 units at $37.93), increasing direct ownership by 9% to 621,721 units (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    11/12/24 6:05:40 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    SEC Filings

    View All

    Semler Scientific Inc. filed SEC Form 8-K: Leadership Update

    8-K - Semler Scientific, Inc. (0001554859) (Filer)

    10/17/25 4:10:11 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events

    8-K - Semler Scientific, Inc. (0001554859) (Filer)

    10/3/25 4:18:26 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 425 filed by Semler Scientific Inc.

    425 - Semler Scientific, Inc. (0001554859) (Subject)

    10/2/25 4:35:26 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    11/12/24 4:15:46 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Leadership Updates

    Live Leadership Updates

    View All

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction

    DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock transaction. In addition, Strive announced the purchase of 5,816 Bitcoin to its corporate treasury at an average price of $116,047 per Bitcoin, for a total purchase price of $675,000,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 5,886. Transaction details: Deal represents an approximately 210% premium, equivalent to approximately $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market clos

    9/22/25 8:15:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Appoints Joe Burnett as Director of Bitcoin Strategy; Targets Owning at Least 10,000 Bitcoins by Year-End 2025 and 105,000 by Year-End 2027

    CAMPBELL, Calif., June 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Joe Burnett as director of Bitcoin strategy. Semler Scientific also announced that it plans to hold 10,000 Bitcoins by year-end 2025, 42,000 by year-end 2026 and 105,000 by year-end 2027, using proceeds from equity and debt financings and cash flows from operations.  "We are excited to have Joe join our Bitcoin strategy

    6/19/25 4:45:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Appoints Natalie Brunell to its Board of Directors

    CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community. "We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Sci

    5/19/25 8:00:00 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Financials

    Live finance-specific insights

    View All

    Semler Scientific® Reports Second Quarter 2025 Financial Results, BTC Holdings of 5,021 and BTC Yield of 31.3% YTD through July 31, 2025

    CAMPBELL, Calif., Aug. 4, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its Bitcoin holdings and other key performance indicators (KPIs). "We have made excellent progress with our Bitcoin treasury strategy," said Eric Semler, executive chairman of Semler Scientific. "We purchased approximately $195.4 million of Bitcoin s

    8/4/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

    CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

    5/13/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

    SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

    4/30/25 8:00:00 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction

    DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock transaction. In addition, Strive announced the purchase of 5,816 Bitcoin to its corporate treasury at an average price of $116,047 per Bitcoin, for a total purchase price of $675,000,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 5,886. Transaction details: Deal represents an approximately 210% premium, equivalent to approximately $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market clos

    9/22/25 8:15:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Reports Second Quarter 2025 Financial Results, BTC Holdings of 5,021 and BTC Yield of 31.3% YTD through July 31, 2025

    CAMPBELL, Calif., Aug. 4, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its Bitcoin holdings and other key performance indicators (KPIs). "We have made excellent progress with our Bitcoin treasury strategy," said Eric Semler, executive chairman of Semler Scientific. "We purchased approximately $195.4 million of Bitcoin s

    8/4/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Announces Earnings Release Date and Live Video Webinar for Second Quarter 2025 Financial Results

    CAMPBELL, Calif., July 21, 2025 /PRNewswire/ --Semler Scientific, Inc. (NASDAQ:SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced it will report financial results for the second quarter ended June 30, 2025, after the close of U.S. financial markets on Monday, August 4, 2025. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a live video webinar at 4:30 pm ET the same day. Eric Semler, executive chairman, Renae Cormier, chief financial officer, and Joe Burnett, director of Bitcoin strategy, will join him on the call. Please submi

    7/21/25 5:48:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care